ÔĽŅ Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Xin Chen, Ph.D.

Investigator

xchen@nhri.org.tw

EDUCATION

Ph.D., Biochemistry, University of Iowa, Iowa City, USA (1994)
B.S., Biochemistry, Nankai University, Tianjing, PRC (1989)

PROFESSIONAL EXPERIENCES

  • Associate Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2006-present)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2002-2006)
  • Postdoctoral Fellow, Institute of Molecular Biology, Academia Sinica, ROC; University of California, Davis, CA, and University of Iowa, Iowa City, USA (1995-2001)

    RESEARCH INTERESTS

    The research interest of Dr. Chen is to study the structure, catalysis and function of prolyl-cleaving dipeptidases, including DPP-IV, FAP, DPP8, DPP9 and DPP2. Among them, DPP-IV is a validated drug target for type II diabetes. In the past few years, Dr. Chenís group has investigated the relationship between the enzymatic activity and quaternary structure of DPP-IV and DPP8, and the substrate specificity of various DPP enzymes and SARS-CoV papain like protease 2. The biological
    functions of these proteases will be the focus of future investigation through proteomics, molecular, cellular and chemical biological methods. Furthermore, potent and selective chemical compounds will be discovered through collaboration with the synthetic chemists to probe the biological function of these proteases in vivo.

    RESEARCH ACTIVITIES & ACCOMPLISHMENTS

    Dr. Chen is involved in anti-diabetic and anti-SARS drug discovery and research. Dr. Chenís lab provides the biological assays, including enzyme expression, purification and characterization, to various screening platforms to support drug discovery projects within DBPR. Her group focuses on the development of anti-diabetes drugs, mainly on two drug targets DPP-IV and PPAR?. In the future, Dr. Chen will continue to contribute in the discovery and development of anti-diabetes drugs, drug target identification, validation and functional studies.

    HONORS & AWARDS

  • NHRI Young Investigator Award, NHRI, Taiwan, 2007
  • Wu-Da-You Memorial Award, NSC, Taiwan, 2007
  • Postdoctoral Fellowship for Outstanding Mainland Chinese, NSC, Taiwan, 1996-1997
  • NIH Postdoctoral Fellowship, Cardiovascular Center, UI, USA, 1995
  • Predoctoral Fellowship, American Heart Association, USA, 1991-1994

    SELECTED PUBLICATIONS

    1.Chou CY, Chien CH, Han YS, Prebanda MT, Hsieh HP, Turk B, Chang GG and Chen X*. Thiopurine Analogs Inhibit Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus. Biochemical Pharmacology, in press, 2008.
    2.Lee HJ, Chen YS, Chou CY, Chien CH, Lin CH, Chang GG and Chen X*. Investigation of the Dimer Interface and Substrate Specificity of Prolyl Dipeptidase DPP8. Journal of Biological Chemistry, 281:38653-38662, 2006.
    3.Chien CH, Tsai CH, Lin CH, Chou CY and Chen X*. Identification of Hydrophobic Interaction Critical for DPP-IV Dimer Formation. Biochemistry, 45:7006-7012, 2006.
    4.Han YS, Chang GG, Jou CG., Lee HJ, Hsu JTA and Chen X*. Papain-Like Protease 2 (PLP2) from SARS-CoV: Expression, Purification, Characterization and Inhibition. Biochemistry, 44:10349-10359, 2005.
    5.Jiaang WT*, Chen YS, Hsu H, Wu SH, Chien CH, Chang CN, Chang SP, Lee SJ and Chen X*. Novel Isoindoline Compounds For Potent and Selective Inhibition of Prolyl Dipeptidase DPP8. Bioorganic and Medicinal Chemistry Letters, 15:687-691, 2005.
    6.Chien CH, Huang LH, Chou CY, Chen YS, Han YS, Chang GG, Liang PH and Chen X*. One Site Mutation Disrupts Dimer Formation in Human DPP-IV Proteins. Journal of Biological Chemistry, 279:52338-52345, 2004.
    (* = Corresponding Author)